Oncotelic Therapeutics Inc. is advancing nanoparticle-based drug delivery strategies through its joint venture entity, positioning the company at the forefront of pharmaceutical innovation that applies ultra-small carrier technologies to enhance existing cancer therapies. The company is pioneering how nanotechnology can improve bioavailability, precision targeting and therapeutic performance of anticancer compounds, with nanoparticle delivery offering significant advantages in pharmaceutical development.
The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics. Oncotelic is now preparing its first-in-human study of an intravenous Everolimus nanoformulation that it codevelops via its subsidiary and partner Sapu Nano. According to the company, this formulation is designed to overcome the absorption and tumor-penetration limits of conventional oral Everolimus by delivering full bioavailability via intravenous nanoparticle delivery.
This advancement represents a critical step in addressing high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates. The nanoparticle approach could potentially transform how cancer drugs are delivered to patients, improving efficacy while potentially reducing side effects through more precise targeting. The technology addresses fundamental limitations of current oral cancer therapies, which often suffer from inconsistent absorption and limited ability to penetrate tumor tissues effectively.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy product development. The company benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures, including its 45% ownership of GMP Bio, which is advancing its own pipeline of drug candidates.
The latest news and updates relating to Oncotelic Therapeutics are available in the company's newsroom at https://ibn.fm/OTLC. The company's progress in nanoparticle drug delivery represents a significant development in cancer treatment technology, with potential implications for improving patient outcomes across multiple oncology indications. As the pharmaceutical industry continues to explore advanced delivery systems, nanoparticle technologies like those being developed by Oncotelic could redefine standards of care for cancer patients worldwide.
